Dupont Capital Management Corp Has $10.21 Million Stake in Abbott Laboratories (ABT)

Dupont Capital Management Corp lifted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 1,633.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 191,415 shares of the healthcare product maker’s stock after buying an additional 180,374 shares during the quarter. Dupont Capital Management Corp’s holdings in Abbott Laboratories were worth $10,214,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the company. Vanguard Group Inc. grew its position in shares of Abbott Laboratories by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 129,786,955 shares of the healthcare product maker’s stock worth $6,308,944,000 after buying an additional 3,241,063 shares during the period. State Street Corp grew its position in shares of Abbott Laboratories by 18.9% during the 1st quarter. State Street Corp now owns 80,499,469 shares of the healthcare product maker’s stock worth $3,574,987,000 after buying an additional 12,806,535 shares during the period. Capital Research Global Investors grew its position in shares of Abbott Laboratories by 45.7% during the 2nd quarter. Capital Research Global Investors now owns 47,589,663 shares of the healthcare product maker’s stock worth $2,313,334,000 after buying an additional 14,918,038 shares during the period. Northern Trust Corp grew its position in shares of Abbott Laboratories by 3.1% during the 2nd quarter. Northern Trust Corp now owns 26,865,706 shares of the healthcare product maker’s stock worth $1,305,942,000 after buying an additional 809,732 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in shares of Abbott Laboratories by 28.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 11,722,088 shares of the healthcare product maker’s stock worth $569,830,000 after buying an additional 2,606,404 shares during the period. Institutional investors own 71.15% of the company’s stock.

Abbott Laboratories (NYSE ABT) opened at $57.07 on Tuesday. The company has a quick ratio of 2.26, a current ratio of 2.69 and a debt-to-equity ratio of 0.72. Abbott Laboratories has a one year low of $38.25 and a one year high of $57.76. The firm has a market cap of $99,336.09, a P/E ratio of 44.94, a price-to-earnings-growth ratio of 2.06 and a beta of 1.06.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.01. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. The firm had revenue of $6.83 billion for the quarter, compared to analyst estimates of $6.72 billion. During the same quarter in the previous year, the firm posted $0.59 earnings per share. The business’s revenue was up 28.8% on a year-over-year basis. equities research analysts expect that Abbott Laboratories will post 2.5 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be paid a $0.28 dividend. The ex-dividend date is Thursday, January 11th. This represents a $1.12 dividend on an annualized basis and a yield of 1.96%. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.27. Abbott Laboratories’s payout ratio is presently 83.47%.

Several research analysts recently weighed in on ABT shares. Zacks Investment Research raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $58.00 price objective on the stock in a research note on Friday, September 22nd. Cowen reissued a “buy” rating on shares of Abbott Laboratories in a research note on Sunday, September 24th. Wells Fargo & Co lifted their price objective on shares of Abbott Laboratories from $57.00 to $64.00 and gave the stock an “outperform” rating in a research note on Thursday, September 28th. Barclays lifted their price objective on shares of Abbott Laboratories from $57.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, September 28th. Finally, BMO Capital Markets reissued a “hold” rating and set a $53.00 price objective on shares of Abbott Laboratories in a research note on Monday, October 2nd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating to the company’s stock. Abbott Laboratories presently has an average rating of “Buy” and a consensus price target of $57.56.

In other news, EVP Daniel Gesua Sive Salvadori sold 96,603 shares of the business’s stock in a transaction on Monday, October 23rd. The shares were sold at an average price of $56.21, for a total value of $5,430,054.63. Following the sale, the executive vice president now owns 142,082 shares of the company’s stock, valued at $7,986,429.22. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Alejandro D. Wellisch sold 2,153 shares of the business’s stock in a transaction on Wednesday, November 22nd. The stock was sold at an average price of $55.86, for a total transaction of $120,266.58. Following the completion of the sale, the insider now directly owns 10,256 shares in the company, valued at approximately $572,900.16. The disclosure for this sale can be found here. In the last ninety days, insiders sold 501,172 shares of company stock worth $27,533,150. Insiders own 0.76% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Dupont Capital Management Corp Has $10.21 Million Stake in Abbott Laboratories (ABT)” was originally reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.com-unik.info/2018/01/02/dupont-capital-management-corp-has-10-21-million-stake-in-abbott-laboratories-abt.html.

Abbott Laboratories Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit